Rexulti sits in the same awkward spot as most of the newer antipsychotics: heavily prescribed, heavily advertised, and priced like a specialty drug. Medicare Part D covered 598,492 Rexulti claims for 94,695 people in 2024 at an average of $1,439.27 per claim, $861 million in total. Every one of those people had coverage. A cash payer sees the whole number.
What makes this page different from a normal brand-drug page is a technicality that matters a lot: FDA has already approved generic brexpiprazole, but nobody is selling it. Everything below was researched on September 4, 2026, and each figure is attributed to the source it came from.
What Does Rexulti Cost Without Insurance?
Acquisition costs come from the CMS National Average Drug Acquisition Cost survey, effective August 19, 2026. That is what a pharmacy pays a wholesaler, not a patient price, and the difference between the two is where pharmacy markup lives. Cash prices come from Drugs.com and SingleCare, both read September 4, 2026. Otsuka does not publish a list price for Rexulti anywhere on its consumer site, which is itself unusual for a drug at this price.
| Option | Low | Average | High |
|---|---|---|---|
| CMS NADAC acquisition cost, one tablet | $49.50051 (4 mg) | $49.53272 (2 mg) | $49.57420 (1 mg) |
| CMS NADAC acquisition cost, 30 tablets | $1,485.02 (4 mg) | $1,485.98 (2 mg) | $1,487.23 (1 mg) |
| Cash price, 30 tablets, any strength (Drugs.com) | $1,527.66 | $1,527.66 | $1,527.66 |
| Discount card price, 30 tablets of 1 mg | $1,458.04 | $1,458.04 | $1,458.04 |
| Average retail, 30 tablets of 1 mg, no card | $2,051.42 | $2,051.42 | $2,051.42 |
| Medicare Part D average paid per claim, 2024 | $1,439.27 | $1,439.27 | $1,439.27 |
| Savings card annual maximum, commercial insurance only | $8,180 | $8,180 | $8,180 |
| For contrast: 30 generic quetiapine tablets (acquisition cost) | $0.69 (25 mg) | $2.57 (200 mg) | $4.64 (400 mg) |
The sources land close together at the bottom and far apart at the top. CMS, Drugs.com and SingleCare’s card price all cluster between roughly $1,458 and $1,528 for 30 tablets, which is about as settled as brand drug pricing gets. SingleCare’s stated average retail price of $2,051.42 sits about $520 above that cluster. Read the gap as pharmacy markup on an unhelped counter transaction, not as the market rate, and treat any quote above $2,100 as a reason to call somewhere else.
What Drives the Price
A generic exists on paper and not in a pharmacy. FDA’s Drugs@FDA record shows Alembic’s ANDA 213683 approved January 13, 2025, covering all six strengths as AB-rated prescription products. Yet CMS’s acquisition-cost file returns zero rows for BREXPIPRAZOLE, and Drugs.com says a generic has been approved but is either unpriced or not commercially available. Approval and launch are different events, and only the second one moves a cash price. Compare that with generic quetiapine at $0.02293 to $0.15480 per tablet in the same CMS file, which is why our Seroquel cost guide lands on $9 to $15 a month.
Dose does not matter. Rexulti’s six strengths run 0.25 mg to 4 mg, and the pharmacy’s acquisition cost varies by less than a cent across all of them. Drugs.com quotes the same $1,527.66 for 30 tablets at every strength. Titrating up does not raise the bill.
Whether anyone runs a discount card. The $593 gap between SingleCare’s $2,051.42 average retail figure and its own $1,458.04 lowest price on the identical 30-tablet fill is the largest swing on this page that a patient controls directly. Our comparison of GoodRx vs. SingleCare covers how to price a prescription both ways before you fill it.
Which pharmacy, and on which day. Chain-level quotes for brand drugs move between sessions and are not stable enough to publish as facts. The average and the card price are stable; the individual chain rows behind them are not. That instability is the practical argument for calling three pharmacies rather than trusting one screenshot.
What kind of coverage you have, if any. Otsuka’s savings card can take a commercially insured patient to $0 with an $8,180 annual ceiling. Nothing on the cash side of the ledger competes with that, which is why the assistance section below matters more than the shopping section.
Cash Price vs. Insurance
For most generics, paying cash beats using insurance. On Rexulti it does not, and it is not close. A commercial plan plus Otsuka’s savings card can take the copay to as little as $0 for both 30-day and 90-day fills, up to 13 uses per calendar year with an annual maximum of $8,180. No cash price in the table above is anywhere near that.
The terms are worth reading rather than skimming, because they are narrow. Otsuka’s savings program terms, read September 4, 2026, require commercial drug insurance and a prescription consistent with FDA-approved labeling. Patients whose prescription is covered in whole or in part by Medicare Part D, Medicaid including managed care, Medigap, VA, DOD or TRICARE are excluded, and anyone who starts receiving such coverage has to stop using the card. There is also a state carve-out that is easy to miss: if a generic alternative is or becomes available, residents of Massachusetts and California are not eligible.
Rexulti’s own guidance for uninsured patients, on the same savings and cost page, is short and honest. It tells you to contact your pharmacy to discuss pricing and payment options, and points you at patient assistance. That is a fair description of the situation. There is no cash program here, so the real work is the application described below.
Because a cash fill does not count toward a deductible or an out-of-pocket maximum, and because one Rexulti fill is a large share of most deductibles, running this drug through a plan is almost always worth more than any discount you could get by paying cash. If you are weighing whether to carry coverage at all, our guide to self-pay vs. health insurance works through that tradeoff.
How to Pay Less
-
Apply to the Otsuka Patient Assistance Foundation first if you are uninsured. OPAF is a 501(c)(3) nonprofit that supplies prescribed Otsuka medicines free of cost to eligible uninsured and underinsured patients, and Rexulti is on its list. Its FAQ, read September 4, 2026, says a standard non-government enrollment can run for a rolling 12 months from approval, and that a complete application needs proof of income for every household member who files a tax return plus proof of a US address. US citizenship is not required, though a US home address is. The patient line is 1-855-727-6274. This is the only route on this page that can take the cost to zero.
-
Run a free discount card on every single fill. SingleCare’s Rexulti page, prices updated September 4, 2026, showed a lowest price of $1,458.04 for 30 of the 1 mg tablets against a $2,051.42 stated average retail price. Discount cards usually do little on brand-only drugs, and a $593 monthly gap is a large exception. Re-check before each refill rather than assuming last month’s number still holds.
-
Price the same script at three pharmacies before you fill it. The distance between what CMS says a pharmacy pays (about $1,485) and what SingleCare says the average retail price is ($2,051.42) is roughly $566 of markup per month. Our fair price checker is a quick way to sanity-check a quote before you hand over a card.
-
Ask about a 90-day prescription. Otsuka’s card language explicitly covers 90-day fills, and cash pharmacies charge their fixed costs per fill rather than per tablet, so fewer fills is usually fewer fees. This is a question for a visit, not a change to make on your own.
-
Ask your prescriber whether an older molecule in the class is appropriate. Generic aripiprazole cost Medicare Part D an average of $63.80 per claim in 2024 across 3.84 million claims, against $1,439.27 for Rexulti. That is a clinical judgment only your prescriber can make, but it is a fair question to raise, and our Abilify cost guide and Vraylar cost guide show what the neighbouring options cost. Never stop or change an antipsychotic on your own.
-
Budget for the prescriber, not just the pills. Rexulti requires an ongoing prescribing relationship, and prior authorizations are routine. Our psychiatrist cost guide covers what visits run, and a free or sliding-scale clinic can often handle prescribing at little or no cost while an assistance application is being processed.
-
If the bill already exists, work the bill. A single month of Rexulti can land as a four-figure pharmacy charge, and a hospital or health-system pharmacy charge is negotiable in ways a retail one is not. Our guide to negotiating medical bills covers the script, and hospital charity care covers the application that can wipe it out entirely.
Bottom Line
Budget $1,458 to $2,051 for a 30-tablet month of Rexulti as a cash payer in September 2026, with roughly $1,528 as the middle of the range and no discount for a smaller dose. CMS puts a pharmacy’s own cost at about $1,485 for those 30 tablets, so a quote above $2,100 is markup rather than the price of the medicine.
The generic is the thing to watch. FDA approved Alembic’s brexpiprazole in January 2025, but nothing has reached the acquisition-cost data or the cash price guides as of September 4, 2026, so ask your pharmacist every few months whether one has launched. Until then, the assistance application is the highest-value hour you can spend on this prescription, and if a pharmacy charge has already turned into a bill you cannot pay, start with our itemized bill guide.